Myricx Bio

Myricx is progressing a pipeline of proprietary differentiated ADCs based on our novel N-myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology.

Based on compelling preclinical efficacy and safety data across multiple solid tumour-associated antigens and cancer cell types, we are prioritising two proprietary, differentiated NMTi-ADCs that target the cancer-associated antigens – B7-H3 and HER2.